Cargando…
T-cell Therapy-Mediated Myocarditis Secondary to Cytokine Release Syndrome
Chimeric antigen receptor (CAR) T-cell therapy is expanding to a wider patient population; however, cytokine release syndrome (CRS) is the most important adverse event of these therapies. Patients suffering from high-grade CRS also develop signs of cardiac dysfunction and frequently manifest vascula...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515743/ https://www.ncbi.nlm.nih.gov/pubmed/32983717 http://dx.doi.org/10.7759/cureus.10022 |